CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 358 enrolled
Drug / intervention
Montelukast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04673422
NCT04673422Phase 3Completed
CompareCT.gov

Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial

Phramongkutklao College of Medicine and Hospital·interventional·Posted Dec 17, 2020·Updated Jul 18, 2023

In Brief

A Phase 3 clinical trial evaluating Montelukast and Placebo for Dengue and 2 related conditions. Completed, enrolled 358 participants across 4 sites.

Detailed Summary

This study aims to determine the efficacy of montelukast in reducing the incidence of dengue warning signs in adult dengue patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue, Dengue With Warning Signs, Dengue Shock Syndrome
CountriesThailand
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartJan 15, 2021
Primary CompletionJun 17, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.5 years ago

Interventions

Montelukastdrug

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter

Placebodrug

A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter